Back to Search Start Over

Thrombotic microangiopathy after kidney transplantation: Analysis of the Brazilian Atypical Hemolytic Uremic Syndrome cohort

Authors :
Silvana Maria Carvalho Miranda
Ida Maria Maximina Fernandes-Charpiot
Pedro Augusto Macedo de Souza
Gerson Marques Pereira
Hong Si Nga
Lilian Monteiro Pereira Palma
Luis Gustavo Modelli de Andrade
Roger Kist
Miguel Ernandes Neto
Valter Duro Garcia
Universidade Estadual Paulista (UNESP)
Universidade Estadual de Campinas (UNICAMP)
Transplant Unit São Jose Rio Preto/FAMERP
Transplant Unit Santa Casa de Misericórdia de Porto Alegre-ISCMPA
Santa Casa de Belo Horizonte
Source :
Scopus, Repositório Institucional da UNESP, Universidade Estadual Paulista (UNESP), instacron:UNESP, PLoS ONE, PLoS ONE, Vol 16, Iss 11 (2021), PLoS ONE, Vol 16, Iss 11, p e0258319 (2021)
Publication Year :
2021

Abstract

Made available in DSpace on 2022-04-28T19:47:04Z (GMT). No. of bitstreams: 0 Previous issue date: 2021-11-01 Background Atypical Hemolytic Uremic Syndrome (aHUS) is an ultra-rare disease that potentially leads to kidney graft failure due to ongoing Thrombotic Microangiopathy (TMA). The aim was evaluating the frequency of TMA after kidney transplantation in patients with aHUS in a Brazilian cohort stratified by the use of the specific complement-inhibitor eculizumab. Methods This was a multicenter retrospective cohort study including kidney transplant patients diagnosed with aHUS. We collected data from 118 transplant centers in Brazil concerning aHUS transplanted patients between 01/01/2007 and 12/31/2019. Patients were stratified into three groups: no use of eculizumab (No Eculizumab Group), use of eculizumab for treatment of after transplantation TMA (Therapeutic Group), and use of eculizumab for prophylaxis of aHUS recurrence (Prophylactic Group). Results Thirty-eight patients with aHUS who received kidney transplantation were enrolled in the study. Patients' mean age was 30 years (24-40), and the majority of participants was women (63% of cases). In the No Eculizumab Group (n = 11), there was a 91% graft loss due to the TMA. The hazard ratio of TMA graft loss was 0.07 [0.01-0.55], p = 0.012 in the eculizumab Prophylactic Group and 0.04 [0.00-0.28], p = 0.002 in the eculizumab Therapeutic Group. Conclusion The TMA graft loss in the absence of a specific complement-inhibitor was higher among the Brazilian cohort of kidney transplant patients. This finding reinforces the need of eculizumab use for treatment of aHUS kidney transplant patients. Cost optimization analysis and the early access to C5 inhibitors are suggested, especially in low-medium income countries. Department of Internal Medicine-UNESP Univ Estadual Paulista Departamento de Pediatria Hospital de Clinicas Universidade Estadual de Campinas, SP Transplant Unit São Jose Rio Preto/FAMERP Transplant Unit Santa Casa de Misericórdia de Porto Alegre-ISCMPA Santa Casa de Belo Horizonte Department of Internal Medicine-UNESP Univ Estadual Paulista

Details

Language :
English
Database :
OpenAIRE
Journal :
Scopus, Repositório Institucional da UNESP, Universidade Estadual Paulista (UNESP), instacron:UNESP, PLoS ONE, PLoS ONE, Vol 16, Iss 11 (2021), PLoS ONE, Vol 16, Iss 11, p e0258319 (2021)
Accession number :
edsair.doi.dedup.....af466803b752598496acfa62f37919eb